Serum amyloid A and high-density lipoprotein cholesterol: Serum markers of inflammation in sarcoidosis and other systemic disorders

European Journal of Clinical Investigation

Volumn 31, Issue 12, 2001, Pages 1070-1077

  Salazar, Albert ^a,b   Pinto X ^a   Mana J ^a  

^a HOSPITAL CLÍNIC   (Spain)

^b NONE   (Spain)

Author keywords

Activity; Cholesterol; Inflammation; Sarcoidosis; Serum amyloid A; Serum markers

Indexed keywords

AMYLOID A PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LIPOPROTEIN;

ACUTE DISEASE; CELL ACTIVATION; CONCENTRATION (PARAMETERS); DISEASE MARKER; INFLAMMATION; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; MACROPHAGE; MONOCYTE; MYELOPROLIFERATIVE DISORDER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVIEW; RHEUMATOID ARTHRITIS; SARCOIDOSIS; SYSTEMIC DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS;

APOLIPOPROTEINS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; CHOLESTEROL, HDL; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MYELOPROLIFERATIVE DISORDERS; SARCOIDOSIS; SERUM AMYLOID A PROTEIN;

EID: 0035791743     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.2001.00913.x     Document Type: Review

References (83)

1. Fahie-Wilson M, Mills R, Wilson K. HDL-cholesterol and the acute phase response following myocardial infarction and acute pancreatitis. Clin Chem Acta 1987;167:197-209.
2. Sammalkorpi K, Valtonen V, Kerttula Y, Nikkila E, Taskinen MR. Changes in serum lipoprotein pattern induced by acute infections. Metabolism 1988;37:859-65.
3. Cabana VG, Lukens JR, Rice KS, Hawkins TJ, Getz GS. HDL content and composition in acute phase response in three species. J Lipid Res 1996;37:2662-2674.
4. Panamonta M, Settasatian N, Kaplan EL, Chaikitpinyo A. Serum cholesterol levels in patients with acute rheumatic fever. Am J Dis Child 1993;147:732-736.
5. Muga R, Tor J, Rey-Joly C, Pardo A, Llobet P, Foz M. Dislipemia e infección por VIH-1 en adictos a drogas intravenosas. Med Clin (Barc) 1993;100:161-3.
6. Grunfeld C, Kotler DP, Shigenaga JK et al. Circulating interferon-alpha levels and hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med 1991;90:154-62.
7. Fernandez-Miranda C, Pulido F, Carrillo JL et al. Lipoprotein alterations in patients with HIV infection: relation with cellular and humoral immune markers. Clin Chim Acta 1998;274:63-70.
8. Schmitz G, Fisher H, Beuck M, Hoecker KP, Robenek H. Dysregulation of lipid metabolism in Tangier monocyte-derived macrophages. Arteriosclerosis 1990;10:1010-19.
9. Slater HR, Packard CJ, Shepherd J. Receptor-independent catabolism of low density lipoprotein. Involvement of the reticuloendothelial system. J Biol Chem 1982;257:307-10.
10. Grove RI, Mazzucco C, Allegretto N et al. Macrophage-derived factors increase low density lipoprotein uptake and receptor number in cultured human liver cells. J Lipid Res 1991;32:1889-97.
11. Svenson KLG, Lithell H, Hallgren R, Selinus I, Vessby B. Serum lipoprotein in active rheumatoid arthritis and other chronic inflammatory arthritides. I. Relativity to inflammatory activity. Arch Intern Med 1987;147:1912-16.
12. Gilbert HS, Ginsberg H. Hypocholesterolemia as a manifestation of disease activity in chronic myelogenous leukemia. Cancer 1983;51:1428-33.
13. Ginsberg H, Grabowski GA, Gibson JC et al. Reduced plasma concentrations of total, low density lipoprotein- and high density lipoprotein cholesterol in patients with Gaucher type I disease. Clin Genet 1984;26:109-16.
14. Le NA, Gibson JC, Rubenstein A, Grabowski GA, Ginsberg HN. Abnormalities in lipoprotein metabolism in Gaucher type I disease. Metabolism 1988;37:240-5.
15. Ginsberg HN, Le NA, Gilbert HS. Altered high density lipoprotein metabolism in patients with myeloproliferative disorders and hypocholesterolemia. Metabolism 1986;35:878-82.
16. Thomas PD, Hunninghake GW. Current concepts of the pathogenesis of sarcoidosis. Am Rev Respir Dis 1987;135:747-60.
17. Hardardottir I, Moser AH, Memon R, Grunfeld C, Feingold KR. Effects of TNF, IL-1, and the combination of both cytokines on cholesterol metabolism in Syrian hamsters. Lymphokine Cytokine Res 1994;13:161-6.
18. Keicho N, Kitamura K, Takaku F, Yotsumoto H. Serum concentration of soluble interleukin-2 receptor as a sensitive parameter of disease activity in sarcoidosis. Chest 1990;98:1125-9.
19. Prior C, Haslam PL. Increased levels of serum interferon-gamma in pulmonary sarcoidosis and relationship with response to corticosteroid therapy. Am Rev Respir Dis 1991;143:53-60.
20. Ina Y, Takada K, Sato T, Yamamoto M, Noda M, Morishita M. Soluble interleukin 2 receptors in patients with sarcoidosis. Possible origin. Chest 1992;102:1128-33.
21. Almenoff JA, Teirstein AS. Clinical significance of serum thermolysin-like metalloendopeptidase and its relationship to serum angiotensin converting enzyme in sarcoidosis. Am J Med 1987;82:33-7.
22. Beutler BA, Cerami A. Recombinant interleukin 1 suppresses lipoprotein lipase activity in 3T3-L1 cells. J Immunol 1985;135:3969-71.
23. Ettinger WH Jr, Hazzard WR. Elevated apolipoprotein-B levels in corticosteroid-treated patients with systemic lupus erythematosus. J Clin Endocrinol Metab 1988;67:425-8.
24. Duff GW. Cytokines and acute phase proteins in rheumatoid arthritis. Scand J Rheumatol Suppl 1994;100:9-19.
25. Liang JS, Sipe JD. Recombinant human serum amyloid A (apoSAAp) binds cholesterol and modulate cholesterol flux. J Lipid Res 1995;36:37-46.
26. Marhaug G, Dowton SB. Serum amyloid A. An acute phase apolipoprotein and precursor of AA amyloid. Baillieres Clin Rheumatol 1994;8:553-73.
27. Kumon Y, Suehiro T, Ikeda Y, Yoshida K, Hashimoto K, Ohno F. Influence of serum amyloid A protein on high-density lipoprotein in chronic inflammatory disease. Clin Biochem 1993;26:505-11.
28. Steinmetz A, Hocke G, Saïle R, Puchois P, Fruchart JC. Influence of serum amyloid A on cholesterol esterification in human plasma. Biochim Biophys Acta 1989;1006:173-8.
29. Van Lenten BJ, Hama SY, de Beer FC et al. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest 1995;96:2758-67.
30. Rocken C, Kisilevsky R. Comparison of the binding and endocytosis of high-density lipoprotein from healthy (HDL) and inflamed (HDL-(SAA) donors by murine macrophages of four different mouse strains. Virchows Arch 1998;432:547-55.
31. Kihara S, Matsuzawa Y, Kubo M et al. Autoimmune hyperchylomicronemia. N Engl J Med 1989;320:1255-9.
32. Ginsberg HN, Goldberg I, Wang-Iverson P et al. Increased catabolism of native and cyclohexanedione modified low density lipoprotein in subjects with myeloproliferative diseases. Arteriosclerosis 1983;3:233-41.
33. Kindman LA, Gilbert HS, Almenoff JS, Ginsberg H, Fagerstrom R, Teirstein AS. High-density lipoprotein cholesterol is reduced in patients with sarcoidosis. Am J Med 1989;86:376-8.
34. Ilowite NT, Samuel P, Ginzler E, Jacobson MS. Dyslipoproteinemia in pediatric systemic lupus erythematosus. Arthritis Rheum 1988;31:859-63.
35. Lahita RG, Rivkin E, Cavanagh I, Romano P. Low levels of total cholesterol, high-density lipoprotein, and apolipoprotein A1 in association with anticardiolipin antibodies in patients with systemic lupus erythematosus. Arthritis Rheum 1993;36:1566-74.
36. Borba EF, Santos RD, Bonfa E et al. Lipoprotein (a) levels in systemic lupus erythematosus. J Rheumatol 1994;21:220-3.
37. Leong KH, Koh ET, Feng PH, Boey ML. Lipid profiles in patients with systemic lupus erythematosus. J Rheumatol 1994;21:1264-7.
38. Ettinger WH, Goldberg AP, Applebaum-Bowden D, Hazzard WR. Dyslipoproteinemia in systemic lupus erythematosus. Effect of corticosteroids. Am J Med 1987;83:503-8.
39. Yamada T, Miida T, Itoh Y, Kawai T, Benson MD. Characterization of serum amyloid A4 as a plasma apolipoprotein. Clin Chim Acta 1996;251:105-12.
40. Malle E, Steinmetz A, Raynes JG. Serum amyloid A (SAA): an acute phase protein and apolipoprotein. Atherosclerosis 1993;102:131-46.
41. Jensen LE, Whitehead AS. Regulation of serum amyloid A protein expression during the acute-phase response. Biochem J 1998;334:489-503.
42. Rygg M. Cytokine-induced differential expression of serum amyloid A genes in fetal and neonatal rabbits. Clin Exp Immunol 1996;103:335-42.
43. Malle E, de Beer FC. Human serum amyloid A (SAA) protein: a prominent acute phase reactant for clinical practice. Eur J Clin Invest 1996;26:427-35.
44. Berendes E, Mollhoff T, Aken HV, Erren M, Deng MC, Loick HM. Increased plasma concentrations of serum amyloid A. an indicator of the acute-phase response after cardiopulmonary bypass. Crit Care Med 1997;25:1527-33.
45. Oezcueruemez-Porsch M, Kunz D, Hardt PD et al. Diagnostic relevance of interleukin pattern, acute-phase proteins, and procalcitonin in early phase of post-ERCP pancreatitis. Dig Dis Sci 1998;43:1763-9.
46. Artl A, Marsche G, Lestavel S, Sattler W, Malle E. Role of serum amyloid A during metabolism of acute-phase HDL by macrophages. Arterioscler Thromb Vasc Biol 2000;20:763-72.
47. Lindhorst E, Young D, Bagshaw W, Hyland M, Kisilevsky R. Acute inflammation, acute phase serum amyloid A and cholesterol metabolism in the mouse. Biochim Biophys Acta 1997;1339:143-54.
48. Clifton PM, Mackinnon AM, Barter PJ. Effects of serum amyloid A protein (SAA) on composition, size, and density of high density lipoproteins in subjects with myocardial infarction. J Lipid Res 1985;26:1389-98.
49. Cabana VG, Gidding SS, Getz GS, Chapman J, Shulman ST. Serum amyloid A and high density lipoprotein participate in the acute phase response of Kawasaki disease. Pediatr Res 1997;42:651-5.
50. Parks JS, Rudel LL. Alteration of high density lipoprotein subfraction distribution with induction of serum amyloid A protein (SAA) in the nonhuman primate. J Lipid Res 1985;26:82-91.
51. Coetzee GA, Strachan AF, Van Der Westhuyzen DR, Hoppe HH, Jeenah MS, De Beer FC. Serum amyloid A-containing human high density lipoprotein 3: density, size and apolipoprotein composition. J Biol Chem 1986;26:9644-51.
52. Marhaugh G, Sletten K, Husby G. Characterization of amyloid related protein SAA complexed with serum lipoproteins (apoSAA). Clin Exp Immunol 1982;50:382-9.
53. Banka CL, Yuan T, De Beer MC, Kindy M, Curtiss LK, De Beer FC. Serum amyloid A (SAA): influence on HDL mediated cellular cholesterol efflux. J Lipid Res 1995;36:1058-65.
54. Moller DR. Cells and cytokines involved in the pathogenesis of sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 1999;16:24- 31.
55. Costabel U, Teschler H. Biochemical changes in sarcoidosis. Clin Chest Med 1997;18:827-42.
56. Winterbauer RH. Current concepts in and modes for measurement of activity in interstitial lung disease. Curr Opin Pulm Med 1995;1:358-62.
57. Müller-Quernheim J. Serum markers for the staging of disease activity of sarcoidosis and other interstitial lung diseases of unknown etiology. Sarcoidosis Vasc Diffuse Lung Dis 1998;15:22-37.
58. Berlin M, Lundahl J, Skold CM, Grunewald J, Eklund A. The lymphocytic alveolitis in sarcoidosis is associated with increased amounts of soluble and cell-bound adhesion molecules in bronchoalveolar lavage fluid and serum. J Intern Med 1998;244:333-40.
59. Baumer I, Zissel G, Schlaak M, Muller-Quernheim J. Soluble intercellular adhesion molecule 1 (sICAM-1) in bronchoalveolar lavage (BAL) cell cultures and in the circulation of patients with tuberculosis, hypersensitivity pneumonitis and sarcoidosis. Eur J Med Res 1998;3:288-94.
60. Shijubo N, Imai K, Shigehara K, Hinoda Y, Abe S. Circulating soluble intercellular adhesion molecule-1 (sICAM-1) in patients with sarcoidosis. Clin Exp Immunol 1996;106:549-54.
61. Ishii Y, Kitamura S. Elevated levels of soluble ICAM-1 in serum and BAL fluid in patients with active sarcoidosis. Chest 1995;107:1636-40.
62. Pforte A, Schiessler A, Kressenstein S et al. ICAM-1 expression on alveolar macrophages and in serum of sarcoidosis patients. J Clin Lab Immunol 1995;46:125-35.
63. Tsutsumi T, Nagai S, Imai K, Setoyama Y, Uchiyama T, Izumi T. Soluble interleukin-2 receptor in blood from patients with sarcoidosis and idiopathic pulmonary fibrosis. Sarcoidosis 1994;11:102-9.
64. Iyonaga K, Suga M, Ichiyasu H, Yamamoto T, Hiraga Y, Ando M. Measurement of serum monocyte chemoattractant protein-1 and its clinical application for estimating the activity of granuloma formation in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 1998;15:165-72.
65. Kobayashi J, Kitamura S. Serum KL-6 for the evaluation of active pneumonitis in pulmonary sarcoidosis. Chest 1996;109:1276-82.
66. Hrycaj P, Wurm K, Mennet P, Muller W. Microheterogeneity of acute-phase glycoproteins in patients with pulmonary sarcoidosis. Eur Respir J 1996;9:313-18.
67. Hamada K, Nagai S, Tsutsumi T, Izumi T. Ionized calcium and 1,25-dihydroxyvitamin D concentration in serum of patients with sarcoidosis. Eur Respir J 1998;11:1015-20.
68. Mañá J, Salazar A, Pujol R, Manresa F. Are the pulmonary function tests and the markers of activity helpful to establish the prognosis of sarcoidosis? Respiration 1996;63:298-303.
69. Takemoto Y, Sakatani M, Takami S et al. Association between angiotensin II receptor gene polymorphism and serum angiotensin converting enzyme (SACE) activity in patients with sarcoidosis. Thorax 1998;53:459-62.
70. Tomita H, Ina Y, Sugiura Y et al. Polymorphism in the angiotensin-converting enzyme (ACE) gene and sarcoidosis. Am J Respir Crit Care Med 1997;156:255-9.
71. Salazar A, Mañá J, Pintó X et al. Low levels of high density lipoprotein cholesterol in patients with active sarcoidosis. Atherosclerosis 1998;136:133-7.
72. Salazar A, Mañá J, Fiol C et al. Influence of serum amyloid A on the decrease of high density lipoprotein-cholesterol in active sarcoidosis. Atherosclerosis 2000;152:497-502.
73. Rubinstein I, De Beer FC, Pras M, Knecht A, Baum GL. Serum amyloid A protein concentrations in sarcoidosis. Isr J Med Sci 1989;25:461-2.
74. Salazar A, Mañá J, Pintó X, Argimón JM, Hurtado I, Pujol R. Effect of low dose corticosteroids on plasma lipids in active sarcoidosis (Abstract). In: Proceedings of the 6th WASOGcMeeting, Kumamoto, Japan- November 8-13 1999. Sarcoidosis Vasc Diffuse Lung Dis 1999;16(suppl. 1):42.
75. Ettinger WH, Klinefelter HK, Kwiterovitch PO. Effect of low dose, short-term prednisone on plasma lipids. Atherosclerosis 1987;63:167-72.
76. Rössner S, Löfmark C. Dyslipoproteinemia in patients with active chronic polyarthritis: a study on serum lipoproteins and triglyceride clearance. Atherosclerosis 1977;28:41-6.
77. Lorber M, Aviram M, Linn S, Scharf Y, Brook JG. Hypocholesterolemia and abnormal high-density lipoprotein in rheumatoid arthritis. Br J Rheumatol 1985;24:250-5.
78. Svenson KLG, Lithell H, Hallgren R, Vessby B. Serum lipoprotein in active rheumatoid arthritis and other chronic inflammatory arthritides. II. Effects of anti-inflammatory and disease-modifying drug treatment. Arch Intern Med 1987;147:1917-20.
79. Bakkaloglu A, Kirel B, Ozen S, Saatci U, Topaloglu I, Besbas N. Plasma lipids and lipoproteins in juvenile chronic arthritis. Clin Rheumatol 1996;15:341-5.
80. Baroni S, Scribano D, Zuppi C, Pagano L, Leone G, Giardina B. Prognostic relevance of lipoprotein cholesterol levels in acute lymphocytic and nonlymphocytic leukemia. Acta Haematol 1996;96:24-8.
81. Mitamura T, Ohno S, Ariga H et al. Lipoprotein cholesterol concentrations in patients with Behçet's disease. Clin Chim Acta 1988;175:277-84.
82. Fernández-Cortijo J, Lima J, Chacón P, Fonollosa V, Simeón CP, Vilardell M. El perfil lipídico del suero en la esclerodermia. Clin Invest Arteriosclerosis 1991;3:1-4.
83. Memon RA, Hussain R, Raynes JG, Lateff A, Chiang TJ. Alterations in serum lipids in lepromatous leprosy patients with and without ENL reactions and their relationship to acute phase proteins. Int J Lepr Other Mycobact Dis 1996;64:115-22.